Biotech Companies

515 companies | Drug discovery and development companies

#	COMPANY	THERAPEUTIC AREAS	STAGE
1.	4D Pharma plc Leeds, United Kingdom	Oncology Immunology Gastroenterology	Preclinical to Phase II (at time of administration)	VIEW
2.	AC Immune SA Lausanne, Switzerland		Phase 2	VIEW
3.	ADMA Biologics, Inc. Ramsey, New Jersey, United States		Commercial + Preclinical	VIEW
4.	AGS Therapeutics Paris, France	Ophthalmology Immunology Infectious Disease+2	Preclinical	VIEW
5.	ASKA Pharmaceutical Co., Ltd. Tokyo, Japan	Gastroenterology	Commercial	VIEW
6.	Aardvark Therapeutics San Diego, USA	Rare Diseases Metabolic	Phase 3	VIEW
7.	AbCellera Vancouver, Canada	Metabolic Immunology Oncology	Phase 2	VIEW
8.	Abcuro, Inc. Newton, Massachusetts, USA	Immunology Oncology Rare Diseases	Phase 2/3	VIEW
9.	Abivax Paris, France	Immunology Gastroenterology	Phase 3	VIEW
10.	Acadia Pharmaceuticals Inc. San Diego, USA	Neuroscience Rare Diseases	Commercial	VIEW
11.	Acelot South San Francisco, California, USA	Metabolic Oncology	Preclinical	VIEW
12.	Acrux Melbourne, Australia	Dermatology Metabolic	Commercial	VIEW
13.	Advanz Pharma London, United Kingdom	Gastroenterology Metabolic Oncology+2	Commercial\|Phase 2\|Phase 3	VIEW
14.	Aerogen Pharma San Mateo, USA / Galway, Ireland	Respiratory	Phase 3	VIEW
15.	Affitech Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)	Oncology Immunology Infectious Disease	Clinical	VIEW
16.	Agios Pharmaceuticals Cambridge, USA	Rare Diseases Hematology Metabolic	Commercial	VIEW
17.	Agomab Therapeutics Antwerp, Belgium	Gastroenterology Rare Diseases	Phase 2	VIEW
18.	Ajou University Suwon, South Korea	Oncology Immunology Neuroscience+2	Phase 3	VIEW
19.	Akebia Therapeutics Cambridge, USA	Rare Diseases	Commercial	VIEW
20.	Akribes Biomedical Vienna, Austria	Dermatology	Preclinical	VIEW
21.	Al-Razi Pharma Industries Dammam, Saudi Arabia		Commercial	VIEW
22.	Alkeus Pharmaceuticals Cambridge, USA	Ophthalmology Rare Diseases	Phase 3	VIEW
23.	Allergy Therapeutics Worthing, United Kingdom		Phase 3 and Phase 1/2	VIEW
24.	Allygen Biosciences Shanghai, China	Oncology Immunology	Preclinical	VIEW
25.	Amarin Corporation plc Dublin, Ireland	Cardiovascular	Commercial	VIEW
26.	Anavex Life Sciences Corp. New York, United States	Oncology	Phase 2\|Phase 3	VIEW
27.	Anocca AB Södertälje, Sweden	Oncology Immunology Infectious Disease	Phase 1	VIEW
28.	Apellis Pharmaceuticals, Inc. Waltham, Massachusetts, USA	Ophthalmology Rare Diseases Immunology	Commercial	VIEW
29.	ApicHope Pharmaceutical Group Co., Ltd. Guangzhou, China	Metabolic Infectious Disease	Phase 3	VIEW
30.	Apogee Therapeutics, Inc. Waltham, USA	Dermatology Respiratory	Phase 2	VIEW
31.	Aprogen Seongnam-si, South Korea	Oncology Immunology	Commercial	VIEW
32.	Aquinas Companies, LLC (Fannin Innovation Studio) Houston, Texas, USA	Oncology Infectious Disease Cardiovascular+2	Phase 2	VIEW
33.	Arcus Biosciences Hayward, United States	Oncology Immunology	Phase 3	VIEW
34.	Arcutis Biotherapeutics Westlake Village, California, United States	Dermatology	Commercial & Phase 1/2	VIEW
35.	Ardelyx Waltham, Massachusetts, USA	Gastroenterology	Commercial	VIEW
36.	Argo Biopharma Shanghai, China	Cardiovascular Metabolic Hematology+2	Phase 2	VIEW
37.	Aristo Pharmaceuticals Private Limited Mumbai, India	Gastroenterology Respiratory	Commercial	VIEW
38.	Ark Biosciences Shanghai, China	Respiratory Infectious Disease Neuroscience	Commercial	VIEW
39.	Arrowhead Pharmaceuticals Pasadena, California, United States	Metabolic	Commercial \| Phase 3 \| Phase 2 \| Phase 1	VIEW
40.	Artica Therapeutics Leiden, Netherlands	Immunology	Preclinical	VIEW
41.	Artificial Axon Labs Cambridge, Massachusetts, USA	Neuroscience	Discovery	VIEW
42.	Arvinas, Inc. New Haven, Connecticut, United States	Oncology Neuroscience	Phase 1-3	VIEW
43.	AskGene Camarillo, California, United States	Oncology Immunology Ophthalmology	Phase 3	VIEW
44.	Asklepion Pharmaceuticals, LLC Baltimore, Maryland, USA		Phase 3	VIEW
45.	Asklepios BioPharmaceutical Research Triangle Park, North Carolina, USA	Metabolic	Phase 1\|Phase 2\|Preclinical	VIEW
46.	Aspen Global Incorporated Grand Bay, Mauritius	Oncology Cardiovascular Metabolic+1	Commercial	VIEW
47.	Assertio Holdings, Inc. Lake Forest, USA	Neuroscience Immunology Oncology	Commercial	VIEW
48.	AtaiBeckley (formerly ATAI Life Sciences) Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025		Phase 2	VIEW
49.	Atara Biotherapeutics, Inc. Thousand Oaks, California, USA	Oncology Immunology	Clinical	VIEW
50.	Atea Pharmaceuticals Boston, Massachusetts, United States		Phase 3 (HCV), Phase 1 planned (HEV)	VIEW
51.	Aucta Pharmaceuticals Basking Ridge, New Jersey, USA	Dermatology Ophthalmology Respiratory	Commercial \| Phase 2 \| Preclinical	VIEW
52.	Autobahn Therapeutics San Diego, USA	Neuroscience	Phase 2	VIEW
53.	Autolus Therapeutics London, United Kingdom	Oncology Immunology Rare Diseases	Commercial + Phase 1/2	VIEW
54.	Avenzo Therapeutics San Diego, USA	Oncology	Phase 2	VIEW
55.	Axalbion Lausanne, Switzerland	Respiratory Ophthalmology Neuroscience	Phase 2	VIEW
56.	Azurity Pharmaceuticals Woburn, USA	Cardiovascular Metabolic Gastroenterology+2	Commercial	VIEW
57.	B.Grimm Pharma Bangkok, Thailand	Cardiovascular Gastroenterology Infectious Disease+1	Commercial	VIEW
58.	BIAL São Mamede do Coronado, Trofa, Porto, Portugal	Cardiovascular Rare Diseases	Phase 2 (lead candidate)	VIEW
59.	BIKEN Foundation Suita, Japan	Infectious Disease	Commercial	VIEW
60.	BIOVIIIx Naples, Italy	Rare Diseases Hematology Oncology	Discovery	VIEW
61.	BRIM Biotechnology, Inc. Taipei, Taiwan	Ophthalmology Rare Diseases	Phase 3	VIEW
62.	BeBioSol India		-	VIEW
63.	BeOne Medicines (formerly BeiGene) Cambridge, Massachusetts, United States (corporate); Basel, Switzerland (post-redomiciliation May 2025)	Oncology	Phase 1-3 and Commercial	VIEW
64.	Beijing Sungen Biomedical Technology Co., Ltd. Beijing, China	Cardiovascular Oncology Infectious Disease	Phase 2	VIEW
65.	Belief BioMed Shanghai, China	Rare Diseases Hematology Neuroscience+1	Commercial	VIEW
66.	BenevolentAI London, United Kingdom	Oncology Immunology Neuroscience+3	Phase 1\|Phase 2\|Preclinical	VIEW
67.	Benitec Biopharma Inc. Hayward, California, USA	Infectious Disease Oncology	Phase 1b/2a (BB-301), Preclinical (other programs)	VIEW
68.	Berg Health Framingham, Massachusetts, USA	Oncology Neuroscience Rare Diseases	Phase 1/2	VIEW
69.	Bharat Biotech Hyderabad, India	Infectious Disease Oncology	Commercial	VIEW
70.	BioCardia, Inc. Sunnyvale, California, USA	Cardiovascular Respiratory	Phase 3	VIEW
71.	BioLineRx Ltd. Modiin, Israel	Oncology Rare Diseases	Commercial	VIEW
72.	BioMarin Pharmaceutical Inc. San Rafael, USA	Hematology Metabolic Cardiovascular	Commercial	VIEW
73.	BioMed Valley Discoveries Kansas City, Missouri, USA	Oncology Immunology Rare Diseases+1	Clinical (Phase 1-2)	VIEW
74.	BioNTech Mainz, Germany	Oncology Immunology Infectious Disease	Phase 1-3	VIEW
75.	BioNTech SE Mainz, Germany	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
76.	Biocase Brasil Itajaí, Brazil		Preclinical	VIEW
77.	Biological E. Limited Hyderabad, India	Infectious Disease Gastroenterology	Commercial	VIEW
78.	Biomea Fusion San Carlos, USA	Metabolic Oncology	Phase 2	VIEW
79.	Bionexus (주식회사 바이오넥서스) Suwon, South Korea		Discovery	VIEW
80.	Biotest AG Dreieich, Germany	Hematology	Phase 2\|Phase 3\|Commercial	VIEW
81.	Biotest AG Dreieich (Frankfurt), Germany	Hematology	Phase 3/Commercial	VIEW
82.	Biovet AD Peshtera, Bulgaria		Commercial	VIEW
83.	BlueRock Therapeutics Cambridge, USA	Neuroscience Cardiovascular Ophthalmology+1	Phase 3	VIEW
84.	Blueprint Medicines Cambridge, USA	Oncology Hematology Immunology+1	Commercial	VIEW
85.	Boostimmune Seoul, South Korea	Oncology Immunology	Preclinical	VIEW
86.	Bota Biosciences Hangzhou, China (International HQ in Lafayette, CA, USA)		Commercial	VIEW
87.	BridgeBio Oncology Therapeutics, Inc. South San Francisco, USA	Oncology	Phase 1	VIEW
88.	BunyaVax Lelystad, Netherlands	Infectious Disease Oncology	Phase 1	VIEW
89.	Burke Therapeutics, LLC Hot Springs, Arkansas, USA	Dermatology	Discovery	VIEW
90.	C-Ray Therapeutics Chengdu, China	Oncology	Preclinical\|Phase 1\|Phase 2\|Phase 3\|Commercial	VIEW
91.	CDR-Life Schlieren, Zurich, Switzerland	Oncology Immunology Ophthalmology	Phase 1	VIEW
92.	CECOS University of Information Technology and Emerging Sciences Peshawar, Pakistan	Oncology Neuroscience Infectious Disease	Preclinical	VIEW
93.	CEPI Oslo, Norway	Infectious Disease	Commercial	VIEW
94.	CG Oncology, Inc. Irvine, USA	Oncology	Phase 3	VIEW
95.	CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland	Oncology Immunology Neuroscience+2	Phase 3	VIEW
96.	CS Pharmaceuticals Limited London, United Kingdom	Ophthalmology Rare Diseases	Phase 2	VIEW
97.	CSM Consulting, LLC United States	Cell Therapy Gene Therapy	-	VIEW
98.	CURE5 Foundation New York, USA	Rare Diseases Neuroscience	Discovery	VIEW
99.	Cal Crop USA USA		-	VIEW
100.	Caldera Therapeutics Cambridge, USA	Immunology Gastroenterology	Phase 1	VIEW
101.	Calico Life Sciences South San Francisco, United States	Oncology Neuroscience Immunology	Phase 2	VIEW
102.	Calidi Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
103.	Camurus AB Lund, Sweden	Neuroscience Rare Diseases Metabolic+1	Commercial	VIEW
104.	CanariaBio Inc. Seoul, South Korea	Oncology	Phase 3	VIEW
105.	Cantargia AB Lund, Sweden	Oncology Immunology	Phase 1 - Phase 2	VIEW
106.	Cardurion Pharmaceuticals Burlington, United States	Cardiovascular	Phase 2	VIEW
107.	Carrick Therapeutics Dublin, Ireland	Oncology	Phase 2	VIEW
108.	Carroll Bio-Consulting Boston, USA	Oncology Rare Diseases	Commercial	VIEW
109.	Cell-Tx Seoul, South Korea	Neuroscience Oncology Ophthalmology	Preclinical	VIEW
110.	Celon Pharma Łomianki, Poland	Neuroscience Oncology Immunology+1	Phase 3	VIEW
111.	Celularity Inc Florham Park, New Jersey, USA	Oncology	Phase 1/2 and Phase 2	VIEW
112.	Center for Neuromusculoskeletal Restorative Medicine Limited Shatin, Hong Kong	Neuroscience Rare Diseases	Preclinical	VIEW
113.	Center of Molecular Immunology (CIM) Havana, Cuba	Oncology Immunology	Commercial	VIEW
114.	Centrexion Therapeutics Boston, Massachusetts, United States	Immunology	Phase 1-3	VIEW
115.	Cerevel Therapeutics Cambridge, Massachusetts, USA		Phase 1-3	VIEW
116.	Chengdu Kanghong Pharmaceutical Group Chengdu, China	Ophthalmology Neuroscience Oncology	Commercial	VIEW
117.	Chiba University Chiba, Japan	Oncology Immunology Rare Diseases+3	Phase 2	VIEW
118.	China Medical System Holdings Ltd. Shenzhen, China	Dermatology Gastroenterology Ophthalmology+1	Commercial	VIEW
119.	China Medical University Hospital (CMUH) Taichung, Taiwan	Oncology Neuroscience Cardiovascular+2	Phase 2	VIEW
120.	Chongqing PegBio Biotechnology Co., Ltd. Chongqing, China	Gastroenterology Hematology Oncology	Phase 3	VIEW
121.	Choose Life Biotech SA Bellinzona, Switzerland	Immunology Infectious Disease Oncology	Preclinical	VIEW
122.	Chung-Ang University Seoul, South Korea	Oncology Cardiovascular Immunology+2	Phase 3	VIEW
123.	Cincinnati Children's Hospital Medical Center Cincinnati, USA	Oncology Immunology Rare Diseases+4	Commercial	VIEW
124.	Circio Holding ASA Lysaker, Norway	Oncology Immunology Gene Therapy	Phase 1/2	VIEW
125.	City of Hope Duarte, California, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
126.	Clasp Therapeutics Rockville, Maryland, USA	Oncology	Phase 1	VIEW
127.	Clinny Bio		-	VIEW
128.	Codexis, Inc. Redwood City, California, USA	Rare Diseases Metabolic	Commercial	VIEW
129.	Coherus BioSciences, Inc. Redwood City, USA	Oncology	Commercial	VIEW
130.	College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences (SRIPMS) Coimbatore, India		-	VIEW
131.	Complement Therapeutics United Kingdom (University of Manchester spinout, with facilities in UK and Germany)	Ophthalmology	Phase I/II	VIEW
132.	Constructor Group Schaffhausen, Switzerland	Oncology Infectious Disease Neuroscience	Preclinical	VIEW
133.	Corline Biomedical AB Uppsala, Sweden	Metabolic Cardiovascular Neuroscience	Phase 2	VIEW
134.	Cosmo Pharmaceuticals N.V. Dublin, Ireland	Gastroenterology Dermatology Infectious Disease	Commercial	VIEW
135.	Coya Therapeutics, Inc. Houston, USA	Immunology	Phase 2	VIEW
136.	Crixmor LLC Malvern, Pennsylvania, USA	Immunology Gastroenterology Oncology	Discovery	VIEW
137.	Cugene Inc. Waltham, USA	Oncology Immunology	Phase 1	VIEW
138.	Cullinan Therapeutics Cambridge, USA	Oncology Immunology	Phase 3	VIEW
139.	CuraTeQ Biologics Hyderabad, India	Oncology Immunology Metabolic	Commercial	VIEW
140.	CuraVac Rixensart, Belgium	Immunology	Phase 1B (completed) \| Phase 2 (in preparation)	VIEW
141.	Curadev Pharma Pvt Ltd Noida, India	Oncology Immunology Metabolic	Phase 1	VIEW
142.	Curasight Copenhagen, Denmark	Oncology	Phase 1-2 Clinical	VIEW
143.	Curatis Liestal, Switzerland	Oncology Neuroscience Respiratory+1	Phase 3	VIEW
144.	Curative Biotechnology Inc Boca Raton, Florida, USA	Infectious Disease	Pre-Clinical\|IND-Enabling Studies	VIEW
145.	CureVac Tübingen, Germany	Oncology Infectious Disease Rare Diseases	Phase 2	VIEW
146.	CytoAgents Pittsburgh, USA	Oncology Immunology Infectious Disease+1	Phase 2	VIEW
147.	CytoDyn Inc Vancouver, Washington	Oncology Immunology	Phase 2 clinical	VIEW
148.	CytoImmune Therapeutics Duarte, USA	Oncology Hematology Immunology	Phase 1	VIEW
149.	CytoSen Therapeutics Orlando (Winter Springs), Florida, USA	Oncology Cell Therapy Immunology	Phase 2	VIEW
150.	CytoTools AG Heidelberg, Germany	Dermatology Cardiovascular Oncology	Phase 3	VIEW
151.	CytoVac Hørsholm, Denmark	Oncology	Phase 2	VIEW
152.	Cytochroma Edinburgh, United Kingdom	Cardiovascular Rare Diseases	Discovery	VIEW
153.	Cytocom, Inc. Fort Collins, Colorado, USA	Oncology Infectious Disease Hematology+1	Phase 2/Phase 3	VIEW
154.	CytomX Therapeutics, Inc. South San Francisco, California, United States	Oncology	Phase 1 (clinical), Preclinical (discovery collaborations)	VIEW
155.	Cytonics Corporation Jupiter, Florida, USA	Immunology	Phase 2	VIEW
156.	Cytonus Therapeutics Carlsbad, California, United States	Oncology Immunology Infectious Disease+1	Phase 1	VIEW
157.	Cytorex Biosciences Weston, Florida, USA	Oncology Metabolic Infectious Disease	Preclinical	VIEW
158.	Cytovation Bergen, Norway	Oncology Rare Diseases	Phase I/II - Phase II	VIEW
159.	Cytovia Therapeutics Aventura, Florida, USA	Oncology Immunology	Phase 1/2	VIEW
160.	Cyxone Malmö, Sweden	Immunology Neuroscience	Phase 2	VIEW
161.	D&D Pharmatech Seongnam-si, South Korea		Phase 2	VIEW
162.	DBV Technologies Châtillon, France	Immunology	Phase 3	VIEW
163.	Dankook University Yongin and Cheonan, South Korea	Oncology Neuroscience Rare Diseases+1	Phase 2	VIEW
164.	Dartmouth College Hanover, USA	Oncology Immunology Neuroscience+2	Phase 3	VIEW
165.	Day One Biopharmaceuticals Brisbane, United States	Oncology Rare Diseases	Commercial	VIEW
166.	Debiopharm Lausanne, Switzerland	Oncology Rare Diseases	Phase 1, Phase 2, Phase 3	VIEW
167.	Dendreon Pharmaceuticals Seal Beach, USA	Oncology	Commercial	VIEW
168.	Development Center for Biotechnology (DCB) Taipei, Taiwan	Oncology Immunology Infectious Disease	Preclinical	VIEW
169.	Dexcel Pharma Or Akiva, Israel	Oncology Cardiovascular Neuroscience+2	Commercial	VIEW
170.	DifGen Pharmaceuticals Miramar, USA	Ophthalmology Neuroscience	Commercial	VIEW
171.	Differential Bio Munich, Germany		Commercial	VIEW
172.	Dizal Pharmaceutical Shanghai, China	Oncology Immunology	Commercial	VIEW
173.	Dolor Therapeutics, Inc. Chicago, USA	Immunology	Preclinical	VIEW
174.	Dompé Farmaceutici Milan, Italy	Ophthalmology Rare Diseases Metabolic+2	Commercial	VIEW
175.	Drugs for Neglected Diseases initiative (DNDi) Geneva, Switzerland	Infectious Disease	Commercial	VIEW
176.	Duality Biologics Shanghai, China	Oncology Immunology	Phase 3	VIEW
177.	Duopharma Biotech Berhad Kuala Lumpur, Malaysia	Oncology Cardiovascular Metabolic+1	Commercial	VIEW
178.	Dyne Therapeutics, Inc. Waltham, Massachusetts, USA		Phase 1/2, Phase 3	VIEW
179.	E-Flask Seongnam, South Korea	Neuroscience Oncology	Phase 1	VIEW
180.	EEE Pharma Maharashtra, India	Infectious Disease Immunology Cardiovascular+1	Commercial	VIEW
181.	ETH Zürich Zurich, Switzerland	Oncology Immunology Neuroscience+4	Discovery	VIEW
182.	EUBREAST Esslingen, Germany	Oncology	Phase 3	VIEW
183.	Edge Therapeutics, Inc. Princeton, New Jersey, USA	Oncology Infectious Disease	Phase 3	VIEW
184.	Edgewise Therapeutics Boulder, USA		Phase 2	VIEW
185.	Eledon Pharmaceuticals Irvine, USA	Immunology	Phase 2	VIEW
186.	Eleven Therapeutics Cambridge, United Kingdom	Infectious Disease	Discovery	VIEW
187.	Ellipses Pharma London, United Kingdom	Oncology	Phase 1/2	VIEW
188.	Emergent BioSolutions Gaithersburg, Maryland, USA	Infectious Disease	Commercial	VIEW
189.	Enanta Pharmaceuticals, Inc. Watertown, Massachusetts, USA	Immunology	Phase 1-2 clinical	VIEW
190.	Eneapharm Labège, France	Gastroenterology Rare Diseases	Clinical	VIEW
191.	Enlivex Therapeutics Ltd. Ness Ziona, Israel	Immunology Oncology Infectious Disease	Phase 2	VIEW
192.	Entact Bio Watertown, USA	Oncology Immunology Rare Diseases	Preclinical	VIEW
193.	Epione Medicine ApS Hvidovre, Denmark		-	VIEW
194.	Eris Therapeutics Limited Ahmedabad, India	Cardiovascular Gastroenterology Dermatology	Commercial	VIEW
195.	Estetra SRL Liège, Belgium	Oncology	Commercial	VIEW
196.	EurimPharm Arzneimittel GmbH Saaldorf-Surheim, Germany	Oncology Immunology Neuroscience+2	Commercial	VIEW
197.	Everest Medicines Shanghai, China	Immunology Oncology Cardiovascular+1	Commercial	VIEW
198.	Evopoint Biosciences Suzhou, China	Oncology Infectious Disease Immunology	Commercial (NDA Stage)	VIEW
199.	Evotec SE Hamburg, Germany	Oncology Neuroscience Infectious Disease+1	Commercial	VIEW
200.	Exelixis Alameda, USA	Oncology	Commercial	VIEW
201.	Exeltis Florham Park, USA (Global HQ in Madrid, Spain)	Neuroscience Respiratory Dermatology+2	Commercial	VIEW
202.	Exlixis		-	VIEW
203.	FNCT Biotech Seongnam-si, South Korea	Oncology Immunology	Preclinical	VIEW
204.	Fishfa Biogenics Rajkot, India	Immunology Infectious Disease Oncology+1	Commercial	VIEW
205.	Flagship Pioneering Cambridge, USA	Oncology Immunology Cardiovascular+2	Discovery	VIEW
206.	Flare Therapeutics Cambridge, MA, USA	Oncology	Phase 1-1B	VIEW
207.	FluGen, Inc. Madison, USA	Infectious Disease	Phase 2	VIEW
208.	Focus Care Pharmaceuticals B.V. Zaandam, Netherlands	Respiratory Neuroscience Cardiovascular+1	Commercial	VIEW
209.	Forma Therapeutics Inc Watertown, USA	Hematology Oncology Rare Diseases	Phase 3	VIEW
210.	Formation Bio New York, USA	Immunology Dermatology Neuroscience	Phase 3	VIEW
211.	Formycon AG Planegg-Martinsried, Germany	Ophthalmology Immunology	Commercial	VIEW
212.	Frontier Medicines South San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
213.	Fundação Butantan São Paulo, Brazil	Infectious Disease	Phase 2	VIEW
214.	Fusion Pharmaceuticals Inc. Hamilton, Ontario, Canada	Oncology	Phase 1\|Phase 2\|Phase 3	VIEW
215.	G. H. Raisoni University Saikheda, India	Oncology Metabolic Neuroscience+1	Discovery	VIEW
216.	GEN İlaç Ankara, Turkey	Oncology Neuroscience Metabolic+3	Phase 1\|Phase 2\|Commercial	VIEW
217.	GENFIT Loos, France	Metabolic	Phase 2	VIEW
218.	Galpha Laboratories Limited Mumbai, India	Infectious Disease Gastroenterology Dermatology	Commercial	VIEW
219.	Gan & Lee Pharmaceuticals Beijing, China	Metabolic Oncology Cardiovascular	Commercial	VIEW
220.	GenAns Biotech Beijing, China	Neuroscience Ophthalmology Oncology	Preclinical	VIEW
221.	Gene Oasis Singapore, Singapore	Oncology Neuroscience Immunology+1	Clinical	VIEW
222.	GeneBiology, Inc. Research Triangle Park, North Carolina, USA	Oncology Neuroscience Gastroenterology	Clinical	VIEW
223.	Genentech South San Francisco, California, United States	Oncology Immunology Rare Diseases+3	Discovery through Commercial	VIEW
224.	Genmab Copenhagen, Denmark	Oncology Hematology Immunology	Commercial	VIEW
225.	George Mason University Fairfax, USA	Oncology Infectious Disease Metabolic+2	Phase 2	VIEW
226.	Georgia Southern University Statesboro, USA	Oncology Infectious Disease Neuroscience+1	Discovery	VIEW
227.	Gesynta Pharma AB Stockholm, Sweden		Phase 2	VIEW
228.	Ghosts Past		-	VIEW
229.	Google (Google DeepMind / Isomorphic Labs) London, United Kingdom	Oncology Immunology Cardiovascular	Preclinical	VIEW
230.	Granite Bio Basel, Switzerland	Immunology	Phase 1	VIEW
231.	Guangzhou Cellprotek Pharmaceutical Guangzhou, China	Neuroscience Cardiovascular Immunology+1	Phase 3 (Planning)	VIEW
232.	HBM Partners Zug, Switzerland	Oncology Immunology Neuroscience+3	Commercial	VIEW
233.	HCW Biologics Inc. Miramar, Florida, USA	Oncology Immunology	Phase 2	VIEW
234.	HERMES Arzneimittel Holding Pullach im Isartal, Germany		Commercial	VIEW
235.	HERVolution Therapeutics Copenhagen, Denmark	Oncology	Preclinical	VIEW
236.	HGFH (Placeholder Entity) N/A		Discovery	VIEW
237.	HIPRA Amer, Spain		Commercial	VIEW
238.	HUN-REN Veterinary Medical Research Institute (VMRI) Budapest, Hungary	Infectious Disease	Discovery	VIEW
239.	HUTCHMED Hong Kong	Oncology Immunology Dermatology	Discovery to Phase III	VIEW
240.	Halozyme Therapeutics San Diego, USA	Oncology Immunology Neuroscience+3	Commercial	VIEW
241.	Hamad Bin Khalifa University (HBKU) Doha, Qatar	Oncology Metabolic Infectious Disease+1	Preclinical	VIEW
242.	Hansa Biopharma Lund, Sweden	Immunology Gene Therapy Oncology	Commercial	VIEW
243.	Hanyang University Seoul, South Korea	Oncology Neuroscience Infectious Disease+1	Phase 2	VIEW
244.	Harbour BioMed Shanghai, China	Oncology Immunology Ophthalmology	Phase 3	VIEW
245.	Healios K.K. Tokyo, Japan	Neuroscience Oncology Ophthalmology	Phase 3	VIEW
246.	Healis Therapeutics Cambridge, USA	Neuroscience	Phase 2/3	VIEW
247.	Heligenics Phoenix, Arizona, USA	Oncology Rare Diseases	Discovery	VIEW
248.	Hemerion Therapeutics Villeneuve d'Ascq, France	Oncology	Phase 1/2	VIEW
249.	Heranova Lifesciences Burlington, MA, USA		Clinical	VIEW
250.	Hevolution Foundation Riyadh, Saudi Arabia	Oncology Neuroscience Rare Diseases	Discovery	VIEW
251.	Holostem S.r.l. Modena, Italy	Ophthalmology Dermatology Rare Diseases	Commercial	VIEW
252.	Hone Bio Bristol, United Kingdom	Oncology Cardiovascular	Preclinical	VIEW
253.	Hong Kong University of Science and Technology (Guangzhou) Guangzhou, China	Oncology Neuroscience Ophthalmology+1	Phase 2	VIEW
254.	Howard University Washington, D.C., USA	Oncology Immunology Cardiovascular	Discovery	VIEW
255.	Hudson Pharmaceuticals Ltd. Dhaka, Bangladesh	Respiratory Ophthalmology Gastroenterology+2	Commercial	VIEW
256.	Humatrix Medical Suzhou, China	Cardiovascular	Preclinical/Early Clinical	VIEW
257.	Huons Co., Ltd. Seongnam, South Korea	Ophthalmology Metabolic	Commercial	VIEW
258.	Hyloris Pharmaceuticals SA Liège, Belgium	Cardiovascular Infectious Disease Oncology+1	Commercial	VIEW
259.	Hyphens Pharma Singapore, Singapore	Dermatology	Commercial	VIEW
260.	IMTR Inc. Tokyo, Japan	Immunology Hematology Gastroenterology	Phase 1/2	VIEW
261.	IPS Biopharma AG Bern, Switzerland	Oncology Infectious Disease	Phase 2	VIEW
262.	ITESO, Universidad Jesuita de Guadalajara Tlaquepaque, Mexico		Discovery	VIEW
263.	Iasis Pharma Kamatero, Greece	Cardiovascular Dermatology Gastroenterology+3	Commercial	VIEW
264.	Idorsia Allschwil, Switzerland	Neuroscience Cardiovascular Immunology+1	Commercial	VIEW
265.	Immorna Biotherapeutics Morrisville, USA	Oncology Infectious Disease Dermatology+1	Phase 2	VIEW
266.	Immuneel Therapeutics Bengaluru, India	Oncology Hematology Immunology	Commercial	VIEW
267.	Immunis, Inc. Irvine, California, USA	Immunology	Phase 1/2	VIEW
268.	Immunocore Abingdon, United Kingdom	Oncology Infectious Disease Immunology	Commercial	VIEW
269.	Immunomic Therapeutics, Inc. Rockville, Maryland, United States	Oncology Infectious Disease	Phase 1 - Phase 2	VIEW
270.	Immunophotonics Saint Louis, Missouri, USA	Oncology Immunology	Phase 2/3	VIEW
271.	Immunovant, Inc. Durham, North Carolina, USA	Immunology Neuroscience Metabolic+1	Phase 3	VIEW
272.	Incyte Wilmington, Delaware, USA	Oncology Hematology Dermatology+1	Commercial	VIEW
273.	Indian Immunologicals Limited Hyderabad, India	Infectious Disease Immunology	Commercial	VIEW
274.	Infinitopes Oxford, United Kingdom	Oncology	Phase 1/IIa	VIEW
275.	Initial Therapeutics South San Francisco, USA	Oncology Rare Diseases	Discovery	VIEW
276.	Innovacell Tokyo, Japan	Gastroenterology	Phase 3	VIEW
277.	Inresa Arzneimittel GmbH Freiburg im Breisgau, Germany	Oncology Infectious Disease	Commercial	VIEW
278.	Insmed Incorporated Bridgewater, New Jersey, USA	Immunology Rare Diseases	Commercial	VIEW
279.	Institute for Bioengineering of Catalonia (IBEC) Barcelona, Spain	Oncology Neuroscience Rare Diseases+2	Preclinical	VIEW
280.	Insud Pharma Madrid, Spain	Neuroscience Oncology Cardiovascular+3	Commercial	VIEW
281.	Intellia Therapeutics Cambridge, USA	Rare Diseases Cardiovascular Neuroscience+2	Phase 3	VIEW
282.	Intelligene Taipei, Taiwan	Infectious Disease	Phase 1	VIEW
283.	International Centre of Insect Physiology and Ecology (ICIPE) Nairobi, Kenya	Infectious Disease	Discovery\|Preclinical\|Phase 2	VIEW
284.	International Livestock Research Institute (ILRI) Nairobi, Kenya	Infectious Disease	Commercial	VIEW
285.	Interventional AnalgesiX Inc. Durham, North Carolina, United States		Preclinical	VIEW
286.	Intrommune Therapeutics New York, USA	Immunology	Phase 1	VIEW
287.	Inventiva Pharma Daix, France	Oncology	Phase 3	VIEW
288.	Ionis Pharmaceuticals, Inc. Carlsbad, California, United States	Neuroscience Cardiovascular Immunology+1	Phase 1 through Commercial	VIEW
289.	Ironwood Pharmaceuticals Boston, USA	Gastroenterology Rare Diseases	Commercial	VIEW
290.	Janux Therapeutics San Diego, California, USA	Oncology Immunology	Phase 1	VIEW
291.	Jeil Pharmaceutical Co., Ltd. Seoul, South Korea	Oncology Cardiovascular Gastroenterology+2	Phase 2	VIEW
292.	Jiayue Pharmaceutical Guangzhou, China	Oncology Immunology Infectious Disease	Phase 3	VIEW
293.	Jubilant Therapeutics Bedminster, NJ, United States	Oncology Immunology	Phase I/II Clinical	VIEW
294.	Jumpcan Pharmaceutical Taixing, Jiangsu, China	Gastroenterology Respiratory Oncology+1	Commercial	VIEW
295.	Junshi Biosciences Shanghai, China	Oncology Immunology Metabolic+1	Commercial	VIEW
296.	KM Biologics Co., Ltd. Kumamoto, Japan	Infectious Disease Hematology Immunology	Commercial	VIEW
297.	Kailera Therapeutics Waltham, MA, USA	Metabolic	Phase 3	VIEW
298.	KaliVir Immunotherapeutics Pittsburgh, Pennsylvania, USA	Oncology Immunology	Phase 1/1b Clinical	VIEW
299.	Kardigan South San Francisco, USA		Phase 2/3	VIEW
300.	Kedrion Biopharma Barga, Italy	Immunology Hematology Rare Diseases	Commercial	VIEW
301.	Kenai Therapeutics San Diego, USA	Neuroscience	Phase 1	VIEW
302.	Keros Therapeutics Lexington, Massachusetts, United States	Hematology Respiratory Cardiovascular	Phase 1-3	VIEW
303.	Khartis Therapeutics, Inc. San Diego, USA	Immunology	Discovery	VIEW
304.	Kiniksa Pharmaceuticals London, United Kingdom	Cardiovascular Immunology Rare Diseases	Commercial	VIEW
305.	Knight Therapeutics Inc. Montreal, Canada	Oncology Hematology Infectious Disease+2	Commercial	VIEW
306.	KromaTiD, Inc. Longmont, USA	Oncology Rare Diseases Gene Therapy+1	Discovery	VIEW
307.	Krystal Biotech, Inc. Pittsburgh, USA	Dermatology Respiratory Oncology+1	Commercial	VIEW
308.	Kura Oncology Inc San Diego, California, USA	Oncology	Phase 1\|Phase 2\|Phase 3\|Approved	VIEW
309.	Kyung Hee University Seoul, South Korea	Oncology Neuroscience Immunology+1	Phase 3	VIEW
310.	LFB USA Framingham, USA	Immunology	Commercial	VIEW
311.	LG Business Research Seoul, South Korea	Oncology Immunology Vaccines	Commercial	VIEW
312.	Laboratorios Bagó Buenos Aires, Argentina	Oncology Hematology Cardiovascular+3	Commercial	VIEW
313.	Laboratorios Pharmor SAS Funza, Colombia		Discovery	VIEW
314.	Laboratorios Vita S.A. La Paz, Bolivia	Respiratory	Commercial	VIEW
315.	Laboratorios Viñas Barcelona, Spain	Dermatology	Commercial	VIEW
316.	Ladophar (Lam Dong Pharmaceutical Joint Stock Company) Da Lat, Vietnam		Commercial	VIEW
317.	Lamark Biotech Ahmedabad, India	Oncology	Preclinical	VIEW
318.	Laurent Pharmaceuticals Montreal, Quebec, Canada		Phase 2/3	VIEW
319.	Lepu Biopharma Co., Ltd. Shanghai, China	Oncology	Commercial	VIEW
320.	LiBo Pharma Corp. New Taipei City, Taiwan	Oncology Hematology Immunology	Phase 2/Phase 3	VIEW
321.	Libio Technology Suzhou, China	Cardiovascular Metabolic	Phase 1	VIEW
322.	Lotus Pharmaceutical Co., Ltd. Taipei, Taiwan	Oncology Neuroscience Cardiovascular	Commercial	VIEW
323.	Luminar Life Sciences Lahore, Pakistan		Commercial	VIEW
324.	Luxembourg Institute of Health Strassen, Luxembourg	Oncology Immunology Infectious Disease	Discovery	VIEW
325.	Mariana Oncology (via Carroll Bio Advisory) Watertown, Massachusetts	Oncology	Phase 1	VIEW
326.	Medac GmbH Wedel, Germany	Oncology Hematology Immunology	Commercial/Phase 3	VIEW
327.	MedinCell Montpellier, France		Commercial\|Phase 3\|Preclinical	VIEW
328.	Medison Pharma Petah Tikva, Israel	Oncology Rare Diseases Immunology+2	Commercial	VIEW
329.	Medley Pharmaceuticals Mumbai, India	Cardiovascular Gastroenterology	Commercial	VIEW
330.	Megalabs Canelones, Uruguay	Oncology Gastroenterology Cardiovascular	Development	VIEW
331.	Meitheal Pharmaceuticals Chicago, Illinois, United States	Oncology Metabolic	Phase 1-3 and Commercial	VIEW
332.	Menarini Stemline New York, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
333.	Mersana Therapeutics Cambridge, USA	Oncology Rare Diseases	Phase 1	VIEW
334.	Merus N.V. Utrecht, Netherlands	Oncology	Commercial (BLA Stage)	VIEW
335.	Mesa Green Pharma Frederick, USA	Neuroscience	Preclinical	VIEW
336.	Metagenomi Emeryville, USA	Hematology Cardiovascular Rare Diseases+1	Preclinical	VIEW
337.	Micro CRISPR Vapi, India	Oncology Hematology Metabolic+1	Preclinical	VIEW
338.	Micropep Technologies Auzeville-Tolosane, France		Preclinical	VIEW
339.	Miltenyi Biotec Bergisch Gladbach, Germany	Oncology Immunology Hematology	Commercial	VIEW
340.	Minovia Therapeutics Tirat Carmel, Israel	Rare Diseases Hematology	Phase 2	VIEW
341.	Mirum Pharmaceuticals Foster City, USA	Rare Diseases	Commercial	VIEW
342.	Moderna Cambridge, USA	Infectious Disease Oncology Rare Diseases+2	Commercial	VIEW
343.	Mogam Institute for Biomedical Research Seoul, South Korea	Rare Diseases Infectious Disease Oncology+1	Discovery\|Preclinical	VIEW
344.	Mucpharm Kogarah, Sydney, New South Wales 2217, Australia	Oncology Rare Diseases	Phase 2	VIEW
345.	Myrio Therapeutics Melbourne, Australia	Oncology	Discovery	VIEW
346.	N4 Pharma Chellaston, Derbyshire, United Kingdom	Oncology	Preclinical	VIEW
347.	NBE Therapeutics Basel, Switzerland	Oncology	Phase 1/2	VIEW
348.	NEOM Tabuk, Saudi Arabia		Commercial	VIEW
349.	NMDP Minneapolis, USA	Hematology Oncology Rare Diseases+1	Commercial	VIEW
350.	Nalu Bio San Francisco, USA		Preclinical	VIEW
351.	Nanocan Therapeutics Corporation Princeton, New Jersey (also noted as National Harbor, MD)	Oncology	Phase I/II	VIEW
352.	Nanogen Pharmaceutical Biotechnology JSC Ho Chi Minh City, Vietnam	Oncology Infectious Disease	Commercial	VIEW
353.	Nanophoria Milan, Italy	Cardiovascular Rare Diseases	Preclinical	VIEW
354.	Nanoscope Therapeutics Dallas, USA	Ophthalmology	Commercial	VIEW
355.	Nantong University Nantong, China	Oncology Neuroscience Immunology+1	Phase 3	VIEW
356.	Naoclis Nantes, France	Oncology	Preclinical	VIEW
357.	Natco Pharma Limited Hyderabad, India	Oncology Cardiovascular Neuroscience+1	Commercial	VIEW
358.	Natural Remedies Bangalore, India	Dermatology	Commercial	VIEW
359.	Navigator Medicines, Inc. Scotch Plains, New Jersey, USA	Immunology	Phase 2a (NAV-240), Phase 1 (NAV-242)	VIEW
360.	Nerviano Medical Sciences Nerviano, Italy	Oncology Hematology	Phase 2	VIEW
361.	Neurocrine Biosciences San Diego, USA	Neuroscience Metabolic Rare Diseases	Commercial	VIEW
362.	Neurogene Inc. New York, NY	Neuroscience Rare Diseases	Phase 2	VIEW
363.	New World Pharmaceuticals, LLC Charleston, South Carolina, United States		Commercial (XRCEL launched)	VIEW
364.	NextCure, Inc. Beltsville, Maryland, USA	Oncology Immunology	Phase 2	VIEW
365.	Nexus Bio Sydney, Australia	Oncology Immunology Cell Therapy+1	Commercial	VIEW
366.	Notogen Inc. Toronto, Canada		Preclinical	VIEW
367.	NovaDigm Consulting Group Rockville, Maryland, USA	Infectious Disease Dermatology	Phase 2	VIEW
368.	Novavax, Inc. Gaithersburg, Maryland, USA	Infectious Disease	Commercial + Phase 3	VIEW
369.	Noveome Biotherapeutics Pittsburgh, Pennsylvania, USA	Ophthalmology Neuroscience Dermatology	Phase 1-2	VIEW
370.	Novonesis Lyngby, Denmark		Commercial	VIEW
371.	Nurix Therapeutics, Inc. San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
372.	Nutshell Therapeutics Shanghai, China (Pudong District, Building E, No. 1976 Middle Gaoke Road)	Oncology	Preclinical to Phase 1	VIEW
373.	Nuvation Bio New York, United States	Oncology	Commercial	VIEW
374.	OSIVAX Lyon, France		Phase 2	VIEW
375.	Oban BioPharma Stamford, USA	Neuroscience	Preclinical	VIEW
376.	OceansBio Co., Ltd. Changwon, Gyeongnam, South Korea (also referenced as Seongnam, Kyonggi-do in some sources)		Commercial (TaVNS) \| Clinical development (iVNS)	VIEW
377.	Ocular Therapeutix, Inc. Bedford, Massachusetts, USA	Ophthalmology	Commercial	VIEW
378.	Odyssey Therapeutics Boston, MA, United States	Immunology Dermatology	Phase 2	VIEW
379.	Okklo Life Sciences Nijmegen, Netherlands	Hematology Immunology Oncology	Phase 1	VIEW
380.	On/Off Therapeutics Paris, France	Oncology Immunology Rare Diseases	Preclinical	VIEW
381.	OncoWise Bio Sydney, Australia	Oncology	Discovery	VIEW
382.	Onconic Therapeutics Gangnam-gu, Seoul, South Korea	Oncology	Approved\|Phase 2\|Phase 3	VIEW
383.	Oncotelic Therapeutics Agoura Hills, California, USA	Oncology Rare Diseases	Phase 1\|Phase 2\|Phase 3	VIEW
384.	Optieum Biotechnologies Toon, Japan	Oncology	Preclinical	VIEW
385.	Orchard Therapeutics London, United Kingdom	Immunology Rare Diseases	Commercial	VIEW
386.	Orizuru Therapeutics Kyoto/Fujisawa, Japan		Clinical Phase 1/1b	VIEW
387.	Oscotec Inc. Seongnam-si, South Korea	Oncology Immunology	Phase 3	VIEW
388.	Pacira BioSciences, Inc. Brisbane, California, USA		Commercial + Phase 1/2/3 programs	VIEW
389.	Panion & BF Biotech Inc. Taipei, Taiwan	Dermatology Infectious Disease Gastroenterology	Commercial	VIEW
390.	Partex NV Eschborn, Germany	Oncology Neuroscience Rare Diseases+1	Phase 2	VIEW
391.	Parvus Therapeutics South San Francisco, USA	Immunology Gastroenterology Metabolic	Phase 1/2	VIEW
392.	Pasithea Therapeutics Corp. Miami Beach, USA	Neuroscience Oncology	Phase 1	VIEW
393.	Phanes Therapeutics San Diego, California, USA	Oncology	Phase 1/2	VIEW
394.	Phanes Therapeutics, Inc. San Diego, California, USA	Oncology	Phase 1/2	VIEW
395.	PharmaMar Colmenar Viejo, Spain	Oncology	Commercial	VIEW
396.	PharmaResearch Co., Ltd. Seongnam-si, South Korea	Ophthalmology	Commercial	VIEW
397.	Pharmaforce (Pty) Ltd Midrand, South Africa		Commercial	VIEW
398.	Pharmaprom Casablanca, Morocco	Oncology Infectious Disease	Commercial	VIEW
399.	Pharvaris N.V. Leiden, Netherlands / Zug, Switzerland	Rare Diseases	Phase 3	VIEW
400.	Pherecydes Pharma SA Romainville, France	Infectious Disease	Phase 2	VIEW
401.	Phibro Animal Health Corporation Teaneck, New Jersey, USA		Commercial	VIEW
402.	PlasmaGen BioSciences Bengaluru (Chamrajpet), India	Hematology Oncology Immunology+2	Commercial/Manufacturing	VIEW
403.	Platinum Life Excellence Biotech Beijing, China	Immunology Hematology	Commercial	VIEW
404.	Prana Biosciences Worcester, USA	Oncology Immunology	Preclinical	VIEW
405.	Precigen Germantown, Maryland, USA	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
406.	Quell Therapeutics London, United Kingdom	Immunology	Phase 2	VIEW
407.	QureBio Shanghai, China	Oncology Immunology	Phase 2	VIEW
408.	RNALead Toulouse, France	Oncology Immunology Infectious Disease	Phase 1	VIEW
409.	Rasan Pharmaceutical Industries Sulaymaniyah, Iraq	Infectious Disease	Commercial	VIEW
410.	Ratio Therapeutics Boston, USA	Oncology	Phase 1	VIEW
411.	Recursion Pharmaceuticals Salt Lake City, Utah, USA	Oncology Rare Diseases Neuroscience	Phase 1-2	VIEW
412.	Regenicin, Inc. Las Vegas, NV, USA		Preclinical	VIEW
413.	Replimune Group, Inc. Woburn, USA	Oncology	Phase 3	VIEW
414.	Revolution Medicines Redwood City, USA	Oncology	Phase 3	VIEW
415.	Ribomic Inc. Tokyo, Japan	Ophthalmology Rare Diseases	Phase 2	VIEW
416.	Ribon Therapeutics Cambridge, MA, United States	Oncology Dermatology Respiratory	Phase 1/2	VIEW
417.	Ridgeline Discovery Basel, Switzerland	Oncology Immunology Metabolic+2	Discovery\|Preclinical\|Phase 1\|Phase 2	VIEW
418.	Rondo Therapeutics Hayward, USA	Oncology Immunology	Phase 1	VIEW
419.	SIFI Aci Sant'Antonio (Catania), Italy	Ophthalmology	Commercial	VIEW
420.	SNIPR Biome Copenhagen, Denmark	Infectious Disease Metabolic	Phase 1b-2a	VIEW
421.	STAR Therapeutics South San Francisco, CA 94080, USA	Hematology Immunology	Phase 3	VIEW
422.	Saffron Pharma Faisalabad, Punjab, Pakistan		Commercial	VIEW
423.	Sama Pharmaceutical Seoul, South Korea	Respiratory Dermatology Gastroenterology	Commercial	VIEW
424.	Sanovel Istanbul, Turkey	Cardiovascular Respiratory Gastroenterology+1	Commercial	VIEW
425.	Santa Ana Bio Alameda, USA	Immunology Dermatology	Preclinical	VIEW
426.	Santhera Pharmaceuticals Pratteln, Switzerland		Commercial/Phase 2	VIEW
427.	Saol Therapeutics Roswell, USA	Neuroscience Rare Diseases	Phase 3	VIEW
428.	Sarepta Therapeutics Cambridge, USA	Neuroscience Cardiovascular Rare Diseases	Commercial	VIEW
429.	Scenic Biotech Amsterdam, The Netherlands	Oncology Immunology Rare Diseases+1	Preclinical to IND-enabling	VIEW
430.	Scholar Rock Cambridge, Massachusetts, USA	Oncology	Phase 3	VIEW
431.	Score Pharma, Inc. Huntsville, AL, USA	Oncology	Preclinical	VIEW
432.	Sebela Pharmaceuticals Roswell, USA	Gastroenterology Dermatology	Commercial	VIEW
433.	Secura Bio Las Vegas, USA	Oncology Hematology	Commercial	VIEW
434.	Senti Biosciences South San Francisco, California, USA	Oncology Immunology	Phase 1	VIEW
435.	Sentien Biotech Lexington, Massachusetts, United States		Phase 1/2	VIEW
436.	Sentinel Oncology Cambridge, United Kingdom	Oncology	Preclinical to Phase 1	VIEW
437.	Shanghai Jeyou Pharmaceutical Co., Ltd. Shanghai, China (Pudong district)	Oncology Respiratory Immunology	Preclinical to Phase 2	VIEW
438.	SinSa Labs Lidingö, Sweden	Infectious Disease Ophthalmology Dermatology	Preclinical	VIEW
439.	Sinotherapeutics Inc. Shanghai, China	Oncology Neuroscience Gastroenterology	Commercial	VIEW
440.	Sionna Therapeutics Waltham, Massachusetts, USA		Phase 2	VIEW
441.	Soleno Therapeutics, Inc. Redwood City, California, USA	Metabolic	Commercial	VIEW
442.	Southern Taiwan University of Science and Technology (STUST) Tainan City, Taiwan	Oncology	Preclinical	VIEW
443.	Spark Biopharma Seoul, South Korea	Oncology Neuroscience	Preclinical	VIEW
444.	Spot Biosystems Palo Alto, USA	Oncology Rare Diseases	Preclinical	VIEW
445.	Spur Therapeutics London, United Kingdom		Phase 1/2 to Phase 3	VIEW
446.	StemGen Milan, Italy	Oncology	Phase 1/Phase 2	VIEW
447.	StemSynergy Therapeutics Miami, Florida, USA	Oncology Rare Diseases	Preclinical and IND-enabling	VIEW
448.	Stemline Therapeutics, Inc. New York, United States	Oncology	Commercial + Clinical Development	VIEW
449.	Stoke Therapeutics Bedford, USA (Moving to Waltham, MA in late 2026)	Neuroscience Ophthalmology Rare Diseases	Phase 3	VIEW
450.	Sun Yat-sen University Guangzhou, China	Oncology Ophthalmology Infectious Disease+1	Commercial	VIEW
451.	SunRock Biopharma Santiago de Compostela, Spain	Oncology	Preclinical	VIEW
452.	Supernus Pharmaceuticals, Inc. Rockville, MD, USA	Neuroscience	Commercial	VIEW
453.	Swedish Orphan Biovitrum AB (Sobi) Stockholm, Sweden	Immunology	Commercial	VIEW
454.	Symmetra Bio Doha, Qatar	Cardiovascular	Discovery	VIEW
455.	TAE Life Sciences Irvine, California, United States	Oncology	Investigator Initiated Trials (IIT) - Early clinical stage	VIEW
456.	TRB Pharma Campinas, Brazil	Ophthalmology Neuroscience Dermatology	Commercial	VIEW
457.	TRG Ventures Hellerup, Denmark	Dermatology Immunology Neuroscience	Phase 3	VIEW
458.	TRIM-edicine, Inc. Columbus, Ohio, USA	Cardiovascular Dermatology	Preclinical	VIEW
459.	TS-VV GmbH Baesweiler, Germany		N/A	VIEW
460.	TVAX Biomedical, Inc. Lenexa, Kansas, United States	Oncology	Phase 2b/3	VIEW
461.	TXinno Bioscience Inc. Yongin-si, South Korea	Oncology Immunology	Phase 1	VIEW
462.	TYG Oncology Mansfield, Nottinghamshire, United Kingdom	Oncology Immunology	Phase 1	VIEW
463.	Tagworks Pharmaceuticals Nijmegen, Netherlands	Oncology	Phase 1	VIEW
464.	Taiho Oncology Princeton, New Jersey, USA	Oncology	Phase 2\|Phase 3\|Commercial	VIEW
465.	Taiho Pharmaceutical Co., Ltd. Tokyo, Japan	Oncology Immunology Neuroscience	Commercial	VIEW
466.	Tailor Bio Cambridge, United Kingdom	Oncology	Preclinical	VIEW
467.	Tamkang University New Taipei City, Taiwan	Oncology Neuroscience Infectious Disease	Discovery	VIEW
468.	Tarsus Pharmaceuticals Irvine, California, United States	Ophthalmology	Commercial/Phase 2	VIEW
469.	TechnoPhage Lisbon, Portugal	Infectious Disease Ophthalmology	Phase 1/IIa through Phase 3 in development	VIEW
470.	Teligene Suzhou, China (US subsidiary: Thousand Oaks, California)	Oncology	Preclinical to Phase II	VIEW
471.	Tempest Therapeutics Brisbane, California, USA	Oncology	Phase 2 and Phase 3	VIEW
472.	Ten30 Bio Alameda, CA, United States	Neuroscience Oncology Hematology	Discovery	VIEW
473.	TerSera Therapeutics Deerfield, IL, USA	Oncology Rare Diseases	Commercial	VIEW
474.	Terran Biosciences Miami Beach, Florida, USA		Phase 1\|Phase 2\|Phase 3\|Commercial (NM-101 FDA cleared)	VIEW
475.	Tetra Pharm Technologies Copenhagen, Denmark		Phase 1 to Preclinical	VIEW
476.	The United Laboratories Hong Kong, China	Metabolic Ophthalmology	Commercial	VIEW
477.	Théa Open Innovation Clermont-Ferrand, France	Ophthalmology	Phase 1\|Phase 2\|Phase 3	VIEW
478.	Tongji University Shanghai, China	Oncology Cardiovascular Neuroscience	Phase 3	VIEW
479.	Tonix Pharmaceuticals Holding Corp. Chatham, New Jersey, USA	Neuroscience Immunology Infectious Disease+1	Commercial	VIEW
480.	Tvardi Therapeutics Inc Sugar Land/Houston, Texas, USA	Oncology	Phase 2	VIEW
481.	U.S. Stem Cell, Inc. Sunrise, Florida, United States	Cardiovascular Immunology	Clinical Development	VIEW
482.	UC San Diego Health La Jolla, USA	Oncology Cardiovascular Neuroscience+1	Commercial	VIEW
483.	Ultragenyx Pharmaceutical Inc. Novato, USA	Rare Diseases	Commercial	VIEW
484.	Unicorn Pharma Unknown		-	VIEW
485.	United Therapeutics Corporation Silver Spring, Maryland, United States		Phase 1-3 and Commercial	VIEW
486.	University of British Columbia Vancouver, Canada	Oncology Infectious Disease Rare Diseases+1	Discovery	VIEW
487.	University of California, Berkeley Berkeley, USA	Oncology Immunology Neuroscience+1	Discovery	VIEW
488.	University of Cincinnati Cincinnati, USA	Oncology Neuroscience Hematology+2	Commercial	VIEW
489.	University of Colorado Boulder Boulder, USA	Oncology Rare Diseases Immunology+1	Discovery	VIEW
490.	University of Essex Colchester, United Kingdom	Oncology Neuroscience Immunology+1	Discovery	VIEW
491.	University of Wisconsin–Madison Madison, USA	Oncology Neuroscience Rare Diseases+3	Commercial	VIEW
492.	Vasa Therapeutics Encinitas, USA	Cardiovascular Metabolic	Phase 1	VIEW
493.	Vaxcyte San Carlos, California, USA	Infectious Disease Immunology	Clinical (Phase 2 and Phase 3)	VIEW
494.	Vertex Pharmaceuticals Boston, USA		Commercial	VIEW
495.	Viking Therapeutics San Diego, USA	Metabolic	Phase 3	VIEW
496.	Visirna Therapeutics Shanghai, China	Cardiovascular Metabolic Hematology	Phase 3	VIEW
497.	Visterra Waltham, USA	Immunology Infectious Disease Oncology	Phase 3	VIEW
498.	Vitane Pharmaceuticals Dubai, United Arab Emirates	Cardiovascular Neuroscience Gastroenterology+1	Commercial	VIEW
499.	Vitra Labs San Francisco, USA		Preclinical	VIEW
500.	Wisdomi Clarkdale, Arizona, USA	Oncology Immunology	Discovery	VIEW